Daiichi Sankyo Company, Limited

Equities

4568

JP3475350009

Market Closed - Japan Exchange Other stock markets 06:30:00 10/02/2026 GMT			5-day change	1st Jan Change
2,983.50 ^JPY	+1.07%		+1.65%	-10.89%

02-04	Daiichi Sankyo Announces First Patient Has Been Dosed in A First-In-Human Phase 1/2 Trial	CI
02-03	AstraZeneca says FDA backs Datroway, seeks more assurance on Saphnelo	AN

Transcript : Daiichi Sankyo Company, Limited - Special Call

Published on 12/16/2025 at 03:06 am GMT - Modified on 12/16/2025 at 10:20 am GMT

S&P Capital IQ

Presenter Speech
Kentaro Asakura (Executives)

[Interpreted] Thank you for your participation. We will now begin Daiichi Sankyo's Science and Technology Day 2025. I am Asakura from Corporate

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Daiichi Sankyo Company, Limited

02-04	Daiichi Sankyo Announces First Patient Has Been Dosed in A First-In-Human Phase 1/2 Trial	CI
02-03	AstraZeneca says FDA backs Datroway, seeks more assurance on Saphnelo	AN
02-03	AstraZeneca Says Breast Cancer Treatment Granted US FDA Priority Review	MT
02-03	Daiichi Sankyo And AstraZeneca Receive Priority Review For DATROWAY For Treatment Of Unresectable Or Metastatic Triple Negative Breast Cancer In The U.S	CI
02-03	AG Barr adds drink brands; Filtronic profit falls	AN
02-03	AstraZeneca, Daiichi Sankyo's Breast Cancer Treatment Wins US Priority Review Status	MT
02-02	Nikkei slides on tech, resources sell-off despite weaker yen	RE
01-30	Daiichi Sankyo Company, Limited, Q3 2026 Earnings Call, Jan 30, 2026
01-30	Daiichi Sankyo's Nine-Month Profit Rises 4%	MT
01-30	Daiichi Sankyo Company, Limited Reports Earnings Results for the Nine Months Ended December 31, 2025	CI
01-28	Berenberg Ups AstraZeneca Price Target on Datroway's Sales Potential in Lung Cancer	MT
01-22	Daiichi and AstraZeneca's Enhertu wins sixth approval in China	AN
01-22	Daiichi Sankyo Appoints Veronika Rozehnal, Ph.D., as Head of Translational Research Center Europe	CI
01-21	National Medical Products Administration Approves Enhertu in China as the First and Only Her2 Directed Dc for the Second-Line Treatment of Patients with Her2 Positive Metastatic Gastric Cancer	CI
01-20	European Stocks Close Lower in Tuesday Trading; UK Unemployment Rises to 5.1%	MT
01-20	AstraZeneca, Daiichi Sankyo Say European Medicines Agency Validates Enhertu Application for Breast Cancer	MT
01-19	Daiichi Sankyo and AstraZeneca cheer EU milestone for cancer drug	AN
01-19	European Medicines Agency Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer	CI
01-13	TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer	CI
01-12	Daiichi Sankyo Company, Limited Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 01:30 PM
01-07	Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for Nanflyta®? Commercialization in Central and Eastern Europe	CI
01-05	Tranche Update on Daiichi Sankyo Company, Limited's Equity Buyback Plan announced on April 25, 2025.	CI
01-02	Daiichi Sankyo to spend roughly 300 billion yen to set up production facilities for targeted cancer medicine, Nikkei reports	RE
12-29	Cardiogeni swings to loss as Daiichi Sankyo deal drops away	AN
12-28	Senhwa?s CX-5461 with Astrazeneca/Daiichi Sankyo?s ADC, Trastuzumab Deruxtecan in Phase 1b HER2+ and Breast Cancer Trial; NCI Submits FDA Application	CI